Introduction
Stem cell transplant research and tissue engineering, in present time, have emerged as a legalized and regulated stem cell treatment option globally, but, scientiically, their success is unestablished. Novel stem cell-based therapies have evolved as innovative and routine clinical solutions by commercial companies and hospitals across the world. Such rampant spread of stem cell clinics throughout UK, US, Europe, and Asia relect the public encouragement of beneits to incurable diseases. However, ever growing stem cell therapy developments need constant dogwatch and careful policy making by government regulatory bodies for prompt action in case of any untoward public concern. Therefore, researchers and physicians must keep themselves abreast of current knowledge on stem cells, tissue engineering devices in treatment and its safe legal limits. With this aim, stem cell scientiic developments, treatment options, and legal scenario are introduced here to beginner or actively involved scientists and physicians. Introduction to stem cell therapy will provide basic information to beginner researchers and practice physicians on engineered stem cell research concepts and present stem cell therapy federal regulations in diferent North American, European, and Asian countries. FDA, CDC, EU, ICMR government policies in diferent countries includes information on the current legal position, ethical policies, regulatory oversight, and relevant laws.
The word "eais-te-am" cell refers to the progenitor cell or human body's master cell means irst original embryonic cell with rejuvenating and restorative capability of regenerating any body tissue cell(s) typically called as "Fountain of Youth." Stem cells can divide and develop diferent cell types during early life and help in repair the body by replenishing the damaged cells in disease, wear, and injury.
Stem cell therapy uses mainly human pluripotent stem cells to restore functions of tissues or organs, to maintain or repair the damaged human tissues or organs caused by trauma, genetic disease, or metabolic disease. The stem cell engineered products are at large available and paradigm shift shows a much greater investment in novel stem cell scafolds, designing new matrices, grafts to treat chronic and incurable diseases.
Four major considerations for successful stem cell therapy and research are:
• Why stem cell clinics need regulation and legalization?
• Purpose and global regulatory norms for stem cell research.
• Reliable stem cell treatment and tissue engineering products.
• Concerns on stem cell treatment regulations and role of government approvals.
Stem cell types and need of human embryogenic cell research and tissue engineering are introduced in Section 2. Purpose and global regulatory norms for stem cell research are summarized in Section 3. Present status of stem cell therapy and clinical practice limitations or alternatives is reviewed with government guidelines in Section 4. Global scenario of stem cell clinical centers to treat diferent diseases and human organs are tabulated in Section 5. Major introduction is how government regulatory authorities deine policies, frame guidelines, and keep watch public concerns and clinical practices at treatment centers globally.
Introduction to stem cell
Stem cells are progenitor cells. There are three types of stem cells: adult stem cells (from umbilical cord blood), human embryogenic cells (from embryo from fertilized eggs), and induced-pluripotent cells (by reprograming adult stem cells to diferentiate into speciic tissue cells). These stem cells share common properties: (1) survive long periods to make more stem cells; (2) up-specialized but capable to develop into speciic cells; (3) develop to do speciic work in the body.
What are human embryonic stem cells?
Human embryonic stem cells were irst isolated and cultured in year 1998 to conirm their unique capabilities. They can transform into any human tissues up to 200 diferent cell types found in the body. Under the right conditions, they behave as evergreen, everlasting, and able to multiply indeinitely to form immortal cell line. This amazing capacity of embryonic stem cells to give rise to any type of tissue has intensiied the search for adult stem cells to assume paracrine functions [1] . Stem cells have plasticity, means they circulate throughout the body and reside wherever needed to promote regeneration of local tissue.
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Why human embryonic stem cells are in active research?
Stem cell research ofers great hope to repair serious life-threatening diseases. The irst clinical trial took place in the United States for spinal cord injury repair [2] . The irst European study was reported in the United Kingdom for blindness repair [3] .
From biologist's standpoint, embryonic stem cell research ofers as a tool to understand the tissue maintenance and repair in health, how disease develops, and its possible treatment. The molecular basis of embryonic stem cells growing in three-dimensional culture environments has explored the molecular control of gut development and associated organs to understand the genetic control of fragile-X syndrome. Other example is Parkinson's disease, currently untreatable and life threat.
What is origin of embryonic stem cell lines?
All human embryonic stem cell lines originate from a 4-to 5-day-old blastocyst. A blastocyst is a hollow ball of around 100 cells. Blastocyst is a left over egg from in vitro fertilization (IVF). Some blastocysts are implanted into the woman's uterus, while the rest are stored in a deepfreezer. After implantation, couple decides what to do with remaining blastocysts. They can continue to store blastocysts for research. Only these donated blastocysts are the source of human embryonic stem cell lines.
New embryonic stem cell line for each research project?
For research, cells are harvested from one 4-to 5-day-old blastocyst. Blastocyst cell multiplies in the laboratory to create a "cell line" able to produce an ininite number of embryonic stem cells. All these cells have same genetic make-up. Many cell lines are kept in not-for-proit stem cell banks. Banks supply these stem cells for research all over the world. Existing cell lines are also exchanged at no cost between laboratories in the context of research programs, under tight legal controls.
Purpose and global regulatory norms for stem cell research

What position do member states take on human embryonic stem cell research?
Diferent countries have diferent legislative provisions among diferent states on human embryonic stem cell research.
In the United States of America, 26 states have active stem cell research legislation policy, while other states have loose policy or no legislative rules for stem cell research and treatment. So far, no state has permited any stem cell product for medical treatment as valid. FDA only approved cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications including certain blood cancers and some inherited metabolic and immune system disorders. Last year, a bill HB 810 passed by Texas Governance Springer has taken irst lead to legalize stem cell treatment as "Right to Have Trial" as unproven therapies at their own risk and cost in its report (htps://legiscan.com/TX/text/HB810/2017). Another bill HB 661 permits chronic ill persons to try early stage approved clinical trial. New bill HB 3236 permits companies to charge patients for unproven therapies. Earlier, Obama Governance declared policy for operating 570 stem cell treatment clinics across country including Beverly Hills, CA, New York, San Antonio, Los Angeles, Austin, Texas, Phoenix, and Scotsdale, AZ [1] .
All 18 countries in the European Union (EU) have stem cell research legislative policy involving human embryonic stem cells, three countries prohibit it (Poland, Latvia, and Slovakia) and the rest have no speciic legislation [2, 3] . The EU has no competence to harmonize the legal situation in Member States. Legislation on cell therapy is based on three directives: (1) In view of the diferent legal situations and practices in US, EU member States and Asia, both US and EU have own clear ethical and legal framework on human embryonic stem cell research funded from respective budget. Major regulatory consideration in policy is on batch consistency, product stability, safety, eicacy, and quality of stem cell-based tissue engineered products through pre-clinical, clinical, and marketing authorization.
In US, FDA and CDC government bodies have laid down stringent guidelines on the use of stem cell treatment. Food and Drug Authority (FDA) keeps dog watch over the performance, standard, and any public concern related with stem cell treatment abuse, defective quality, options of tissue engineering for right purpose. In case of non-compliance, irregularities, illicit, and unlawful gain, FDA warns stem cell center, and may take precautionary or prohibitive action. Major stem cell clinics are opened for certain organ diseases to recover them. Notable examples are bone and joint disease, erectile dysfunction, neck and back pain, oral and maxillofacial surgery, tendons, and arthritis [5] [6] [7] [8] [9] [10] . For stem cell therapy, FDA approves stem cell clinic for transplantation purpose. FDA deines and regulates diferent stem cell-based therapies and diferent stem cell products for safe use. Tissue Practice (GTP) with guidelines how biologic drug and device regulations apply to cellular and genetic therapies [11] . FDA developed a regulatory framework in three areas: (1) preventing use of contaminated cells or tissues; (2) preventing the cell and tissue contamination by adequate processing; and (3) clinical safety of all cells and tissues. All these areas of framework control both cell and tissue-based products as mass produced drugs [12] . However, several agencies, like American Red Cross, American Society of Clinical Oncology, and Society of Assisted Reproductive Techniques, clariied the role of FDA limited to allogeneic tissue transplants to control spread of communicable diseases means the stem cell transplantations are medical procedures. FDA division "Center for Biologics Evaluation and Research (CBER)" regulates cell-based therapy, and already approved several ApliGraf®, Carticel®, and Epicel® products. The manipulated autologous cells for somatic cell therapy need approval as investigational new drug (IND). However, ATMP minimally manipulated, labeled, or advertised for homologous use, not combined with drug or device, do not require FDA approval. Of course, FDA has wide regulatory coverage including isolation of stem cell rich fractions for orthopedic use, breast augmentation, and 5-day blastocyst transfer as equivalent drug mass production. In general, regulation applies to cells and tissues (HCT/Ps) used for implementation, transplantation, infusion, and transfer into human recipient.
Two regulatory guides for industries were released by FDA. In the year 2007, "Guidance for industry: Regulation of HCT/Ps-Small Entity Compliance Guide" and other in the year 2009, "Guidance for industry on Current Good Tissue Practice and Additional Requirements for Manufacturers of HCT/Ps" [13] . Clinical trials using mesenchymal stem cells fall in the IND category. In FDA regulation policy, physicians may administer stem cell-based products in patients by two ways: (1) compassionate use or expanded access to investigational drugs and biological products without interfering conduct of clinical investigations; (2) of-label prescription of FDA approved stem cell products at full discretion of physician. A new draft 21 CFR 1271 15(b) guideline for industry "Same Surgical Procedure Exception" states three criteria advised to physicians: (1) autologous use or remove HCT/Ps from individual and implant them into same individual; (2) implant the HCT/Ps within same surgical procedure; (3) HCT/Ps must remain in their original form (rinsing, cleaning, sizing, shaping, and manufacturing is permited). All guidelines, 21 CFR 1271(a), 14(b), and 15(b) exceptions, prohibit the claim of "practice of medicine" of 361 products without FDA compliance. To date, FDA has not approved any stem cell medical product in market place. Moreover, physicians claim of performing innovative surgical procedures (as practice of medicine art not directly regulated by FDA) falling under regulatory exception mentioned in 21CFR 1271 Section 361 Public Health Service (PHS) Act for human cell-tissue-based products (HCT/Ps) in practice of medicine without spreading communicable disease [14] . In contrast, Section 351 of PHS Act deines the premarketing review and FDA approval of drugs, biological products or medical devices.
In the year 2014, two new draft guidelines amended 21CFR 1271.10 and 21CFR 1271.20 regarding Section 361 enacted autologous HCT/Ps only if they are "minimally manipulated" for advertisement or labeling purpose (using of water, crystalloids, sterilizer, or storage preservative) without any clinical safety concern. For example, lipoaspirate SVF for adipose derived stem cell treatments (by autologous HCT/Ps) of Parkinson disease and multiple sclerosis fail to comply 21 CFR 1271.10 for homologous use because processing HCT/Ps breaks down and eliminates structural cushion and support components so altered original relevant reconstruction, repair, or replacement characteristics of stem cells. It puts them in drug, device, and biological product 361 category requiring premarketing FDA approval. However, combination standards (minimum manipulation and homologous use) allow drugs, device, biological products as exempted investigational new drug or device for premarketing approval with assurance of conducting premarketing trial with safety and eicacy. Companies can advertise FDA-cleared investigational new drugs or device exemptions to gain proits from sale in compliance with federal regulations without known safety and eicacy of products. For interested readers, "minimal manipulation" means "processing that does not alter the original relevant characteristics of tissues related to tissue utility for reconstruction, repair, or replacement." In the year 2014, third draft regulation "HCT/Ps from Adipose Tissue: Regulatory Considerations" states that processing to isolate nonadipose tissue (without subsequent cell culture or expansion) is more than minimal manipulation. Stem cell business centers and clinics may operate sale of unproven and unlicensed cell-based interventions without FDA compliance using three said guidelines. Now, it requires considerable FDA efort to design inal regulatory draft.
The current framework in EU was adopted in year 2007 and subsequently renewed as HORIZON 2020 for the duration (2014-2020) to frame the EU's new research and innovation program "triple lock system."
• First and foremost, national legislation is respected-EU projects must follow the laws of the country in which research is carried out;
• In addition, all projects must be scientiically validated by peer review and must undergo rigorous ethical review;
• Finally, EU funds may not be used for derivation of new stem cell lines, or for research that destroys embryos (blastocysts)-including for the procurement of stem cells.
The program operates on a botom-up basis. European Commission does not publish calls for proposals speciically for research using human embryonic stem cells. Scientists propose the methods and materials for a particular study. EU research allows fair comparison of diferent stem cell types to ind the best cell source for a particular research or clinical application.
Regulatory framework in Asia has no well-deined regulation and policy on stem cell-based products and clinical use. It amounts the risk to patients of physical harm and high inancial exploitation. Currently, clinics and pharma companies do not follow clinical trials under regulatory framework or have no national guidelines to follow. Some guides were released as guidelines to clinical trials shown in Table 1 . [15] . In spite of all, ISSCR recommendations remain as undeined code of professional conduct to assure safety due to no harmony between laboratory-based research and use of approved stem cell-based products with policy diferences in diferent continents [16] . Legislation must regulate scientiic progress from lab to clinic in public interest. Public must have conidence in clinical beneits. The public interests may be protected by guidelines for: (1) stem cell-based product is safe, pure, potent for general practice GTP, GMP, and GCP requirements; (2) pre-clinical evidence available on proof-of-principle and safety in animal models; (3) new non-invasive biodistribution monitoring by markers and tumors for clinical trials; (4) preference to patient safety by risk-based approach in granting regulatory approval with conditional marketing authorization.
Ethical guidelines for biomedical research in India on human subjects: section V
How much have the US and EU spent on human embryonic stem cell research?
In the years 2007-2017, the EU has funded 27 collaborative health research projects involving the use of human embryonic stem cells with an EU contribution of about €157 million. Human embryonic stem cell research projects represent approximately one-third of health projects on all forms of stem cells.
In addition, the European Research Council has funded 10 projects for an EU inancial contribution of about €19 million, and there have been 24 Marie Skłodowska-Curie actions involving human embryonic stem cell research worth €23 million.
Stem cell treatment and tissue engineering products
Stem cell therapy: a success or a myth
Stem cell treatment is a new option of organ transplantation or tissue and cell transplantation. Stem cells in culture behave diferently from the tissue cells behave inside body. As a result, the progenitor cells and embryonic cell behavior entirely depends on media conditions, physiology of cultured cells, environment of breeding, action of added growth factors, vital molecules, additives, [18] . Stem cell treatment centers charge prospective patients privately for simple stem cell therapy by bone marrow or peripheral blood liposuction, enzyme digestion, ultrasonic cavitation to prepare stromal vascular fraction (mixture of ibroblasts, endothelial progenitor cells, pericytes, mesenchymal stroma cells, and adipocytes) as therapeutic injection given to said patients or industries manufacture commercial stem cell therapy products without any product regulatory information to patients.
For clinical and commercial use, regulatory challenges are safety testing, in vitro functional assays, potency assays, pre-clinical, or clinical trials. The safety testing includes assays for microbial, fungal, endotoxin, mycoplasma, viral contamination, karyotyping testing, and enriched cell population. In vitro functional and potency assays act a surrogate measure of clinical efectiveness and validity to meet standards and control. In support, pre-clinical trial on experimental toxicity animal models such as immuno-compromised or tumorigenic animals, in vitro manipulation, administration route, and clinical trials with complete safety and sound ethics are necessary [19] . These characteristics establish the potential of these cells for tissue repair after injury or disease so called "stem cell therapies" as stem cell medicinal products made out of minimal manipulation of any target cell type destined for clinical application to improve defective function in the body. Presently, human embryonic stem cells (hESCs) are used in 13% of cell therapy procedures; fetal stem cells in 2%, umbilical cord stem cells in 10%, and adult stem cells in 75% of treatments [20] . Any use of such cell-based medicines is subject to authorization and controls, including their manufacture.
Clinical development for irst-in-man study plan
Study design should demonstrate safety endpoints, eicacy, and its action for proposed clinical trial of new investigational medicinal product (EMEA/CHMP/SWP/28367/07). Safety endpoints may be deined on theoretical basis or any toxicity endpoint. The eicacy assessment should be related to pharmacodynamic efect of ATMP. A safe and minimal efective treatment dose should be identiied. The presence of stem cells intended at desired location should be investigated by selected diferentiation biomarkers to facilitate in vivo monitoring the stem cells during the time of administration in patients and their follow-up in vivo efect to establish long-term eicacy.
Are there alternatives to embryonic stem cells?
Embryonic stem cells have peculiar properties and functions uncommon in other natural cell types. Induced-pluripotent stem cell discovery as an alternative was awarded Nobel Prize in the year 2012 conirming many similar properties common with embryonic stem cells [21] . These cells are in use since then for drug development and screening new medicines. It is believed that drug development will be up to the clinical standard for therapeutic purposes in the future. In recent years, development of induced-pluripotent stem cells has opened new vista of stem cell restoration, repair, rejuvenation, and treatment research as adjuvant therapy.
There are various types of "tissue-speciic" or "adult" stem cells. These cells are useful in speciic applications. They make the limited number of cells found in the tissue from which they were isolated. So, they are limited in their potential as a clinical application of research. The expansion of adult stem cells in culture may be the answer, but extensive cultures of human adult cells may change their intrinsic properties in vivo, rendering them unit for restoring injured or diseased tissue in patients.
Concerns on stem cell treatment regulations
There are concerns raised in the media about uncertain diferentiation and matched neotissue functions after stem cell therapy treatment. The unconirmed outcome of new techniques ofers new possibilities of successful treatment in patients with diicult or untreatable conditions. Stem cell therapy techniques have beneits and risks. Speciic rules were introduced in the European Union (EU) in 2007 [22] to ensure appropriate authorization, supervision, and control of cell therapy medicines to reduce and manage the risks.
Recent media reports highlight the need of public authorities' atention to enforce their legal responsibilities in favor of patients taking restricted or limited treatment in compliance with relevant quality standards, material authenticity, treatment protocols, and supervised patient follow-up measures. The protection of patients is the core rule. Safety and eicacy of stem cell transplant products rule the quality and engineered tissue manufacturing of these products that are set out in good-manufacturing-practice (GMP) requirements. These are globally recognized standards for quality assurance in the production and control of stem cell products. Security and control of medicines derived from stem cell manipulation is tightly controlled by the FDA in US and EU [23] .
Present time, manufacturers avoid compliance with quality standards. Inappropriate unapproved treatment deinition or reclassiication without mandate of competent authorities for control of stem cell products, may expose patients to cross-contaminated cell preparations, and result in short-and long-term risks to individual patients.
How is stem cell treatment clinics regulated in diferent countries?
In a very short span of 10 years, over 600 stem cell clinics were opened with unproven claims and unapproved treatment deinition in the name of some beneits to individual diseases. Competent authorities in diferent countries have laid down ethical or regulatory policies.
Globally, the present major focus is on stem cell therapy in inding new options of incurable diseases with following objectives:
• to promote advances in the treatment of infertility
• to increase knowledge about the causes of congenital disease
• to increase knowledge about the causes of miscarriages
• to develop more efective techniques of contraception
• to develop methods for detecting the presence of gene or chromosome abnormalities
• to increase knowledge about the development of embryos
• to increase knowledge about serious disease
• to enable any such knowledge to be applied in developing treatments for serious disease.
Licensed research is permited on embryos created in vitro for its limited use in fertility treatment research within 14 days of harvesting cells. Human Reproductive Cloning Act (2001) does not permit cell nuclear replacement, or any other technique, to create a child or human reproductive cloning. The Human Tissue Act 2004 [42] regulates the use of human biological materials.
Ethical and regulatory oversight
The regulatory Human Tissue Authority (HTA), the HFEA and the Medicines and Healthcare products Regulatory Agency (MHRA), Gene Therapy Advisory Commitee (GTAC) are research ethics bodies examine and issue reports on ethical issues relating to stem cell research [43] .
Major concerns of stem cell therapy and loopholes in stem cell research
Major concerns are:
• Where do the embryos come from to create stem cell lines for clinical use?
All the human embryonic stem cell lines currently in use come from 4-to 5-day-old embryos left over from in vitro fertilization (IVF) procedures. In IVF, researchers mix a man's sperm and a woman's eggs together in a lab dish. Some of those eggs get fertilized. At about 5 days, the egg divides to become a hollow ball of roughly 100 cells called a blastocyst. These early embryos (blastocyst) are implanted into the woman's uterus to develop pregnancy.
For research, unused blastocysts are stored in the IVF clinic freezer for following use in future:
• Continue paying to store the embryos in freezer
• Defrosting the embryos, which destroys them, so, they are kept in freezer
• Donation of the embryos for supervised adoption
• Choice to donate the frozen embryos for research. These donated embryos are the main source of human embryonic stem cell lines.
Some embryonic experimental stem cell lines also come from embryos carrying harmful genetic mutations like cystic ibrosis or Tay Sachs disease. These are discovered by genetic testing prior to implantation. People who donate leftover embryos for research go through an extensive consent process. Under national and international regulations, no human embryonic stem cell lines can be created without explicit consent from the donor and without stringent regulatory protocols.
• Do embryonic stem cell lines come from aborted fetuses?
No. Embryonic stem cells only come from 4-to 5-day-old blastocysts or younger embryos otherwise it is bad criminal clinical practice.
• Does creating embryonic stem cell lines destroy the embryo?
In most cases, Yes. The hollow blastocyst-source of embryonic stem cells-contains a cluster of 20-30 cells called the "inner cell mass." These are the cells that become embryonic stem cells in a lab dish. The process of extracting these cells destroys the embryo. There is a second method that creates embryonic stem cell lines without destroying the embryo. Instead, scientists take a single cell from a very early stage IVF embryo and can use only one cell to develop a new line. The process of removing one cell from an early stage embryo has been done for many years as a way of testing the embryo for genetic predisposition to diseases such as Tay Sachs. This process is called "preimplantation genetic testing."
Alternatives of embryonic stem cells
New alternatives are emerging to replace controversial embryonic stem cells. Notably, adult stem cells, pluripotent cells are promising sources.
• Are adult stem cells as good-or beter-than embryonic stem cells?
Adult stem cells unlike embryonic stem cells can grow only to follow certain cell paths. The adult stem cells do not grow indeinitely in the lab, unlike embryonic stem cells, and they are not as lexible in the types of diseases they can treat. To establish the claims, large trials with both adult and embryonic stem cells are needed to know the value of adult stem cells.
• Do iPS cells eliminate the need to use embryos in stem cell research?
Induced-pluripotent stem cells, or iPS cells, represent another type of cells that could be used for stem cell research. The iPS cells are adult skin cells. They can be genetically "reprogramed" to appear like embryonic stem cells. The technology to generate human iPS cells was pioneered by Shinya Yamanaka in 2007 [44] .
• Stem cell research may not lead to human cloning because signiicant regulatory and advisory body has restrictions on reproductive cloning throughout world.
Scope of stem cell therapy: what clinics ofer beneits from stem cell therapy?
Stem cell therapy, in some clinics, is making claims of healing based on new investigational personalized trials. Some clinical conditions are claimed to have limited beneit from stem cell therapies in recent years are mentioned in For investigational treatment, consumers need to discuss with doctor to know the potential risks and beneits out of SCBP-based treatment with clear information of mandatory EU or FDA or country approval and regulation for clinical trial study before giving consent to participate in study. Consumers often do not know about SCBP product safety and eicacy outside EU and USA. Consumers should be aware of regulatory authority guidelines and safety, eicacy regulations (risk/beneit evaluation) covering SCBPs in countries before taking decision of treatment in those countries. Safety concerns of SCBPs mainly are: possible cell migration from site of administration to diferentiate into inappropriate cell types at unexpected tissue sites, excessive new cell growth and tumor, or cancer development.
In nutshell, there is a mixed claim of stem cell therapy success, because of unfounded theory, trials, misguided treatments, and no clinical established research to justify the therapy Beter wound repir htps://books.google.co.in/books?isbn=111997139X 
